EssilorLuxottica has released new six-year clinical data, reinforcing the long-term efficacy of Essilor Stellest lenses in managing myopia progression and axial elongation in children and young adults.
The findings were presented at the 2025 China Optometry and Ophthalmology Conference (COOC) by Professor Jinhua Bao from the Eye Hospital of Wenzhou Medical University (China), the principal investigator of the clinical trial.
The study began in 2018 with children aged between eight and 13 years old. After completing the initial five-year phase, participants continued wearing Essilor Stellest lenses for an additional two years to assess the long-term impact on myopia progression.
By the time of the sixth-year follow-up, the participants were aged between 14 and 19 years. The six-year results showed that Essilor Stellest lenses slowed myopia progression by 1.95D (57%) and slowed axial elongation by 0.81 mm (52%),1 compared to an extrapolated single-vision lens control group* model based on data from the first two years of the clinical trial. The findings demonstrate the continued efficacy of Essilor Stellest lenses, with effects sustained up to 19 years of age.
The findings demonstrate the continued efficacy of Essilor Stellest lenses, with effects sustained up to 19 years of age.
Olga Prenat, Head of Medical and Professional Affairs at EssilorLuxottica, said the strong response at COOC 2025 “highlights the widespread adoption of Essilor Stellest lenses as a trusted, proven tool for ECPs in China and worldwide, supporting long-term myopia management, while addressing the global myopia epidemic”.
In addition, five-year efficacy data, recently published in Eye and Vision, demonstrated that Essilor Stellest lenses significantly slowed myopia progression and axial elongation over five years,*2 saving an average of three years of myopia development.†2,3
The study also showed that the risk of progressing to high myopia (defined as -6D or worse) dropped from 38% in the extrapolated single-vision lens control group to just 9% in the Essilor Stellest lenses group.2
*Compared to the 60-month progression of the extrapolated control group (predicted average annual decrease in SER by 9.7% based on the initial two-year control group, Smotherman C, et al. IOVS 2023;64:ARVO E-Abstract 811 and compared to the 60-month progression of the extrapolated control group (predicted average annual decrease in AL by 15% based on the initial two-year control group, Shamp W, et al. IOVS 2022;63:ARVO E-Abstract A0111.
† The initial 24-month myopia progression of 50 myopic children wearing single vision lenses in the two-year prospective, controlled, randomised, double-masked clinical in Wenzhou China were compared to the 60-month follow-up of 43 children wearing Essilor Stellest lenses.
References
- EssilorLuxottica. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 6-year follow-up study. 2025. Data on file.
- Li X, Huang Y, Bao J, et al. Myopia control efficacy of spectacle lenses with highly aspherical lenslets: results of a 5-year follow-up study. Eye and Vision. 2025 Mar 5;12(1):10. Available at: iovs.arvojournals.org/article.aspx?articleid=2794414 [accessed April 2025].
